ICON Plc (ICLR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ICON Plc (ICLR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10166
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ICON plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. It provides a range of specialized services that span the entire lifecycle of product development. The company’s service portfolio includes adaptive trials, biosimilars, clinical research services, commercialization and outcomes, consulting, functional services provision, medical imaging, laboratory services, resourcing solutions and strategic support and tactical solutions for traditional, in vitro diagnostic, and software devices. The company offers research services in areas such as cancer, genomics, central nervous system, cardiovascular, endocrine and metabolic disorders, gastrointestinal, medical device, nonalcoholic steatohepatitis (NASH), ophthalmology, rare and orphan diseases, transplant and immunology, vaccines, women’s health therapeutics and other therapeutic areas. ICON is headquartered in Dublin, Ireland.

ICON Plc (ICLR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ICON Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ICON Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ICON Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ICON Plc, Medical Devices Deals, 2012 to YTD 2018 10
ICON Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ICON Plc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Icon Completes Acquisition Of Clinical Trial Services Business From Cross Country Healthcare For Up To US$56 Million 12
Venture Financing 13
Aptiv Solutions Raises US$5.7 Million In Venture Financing 13
Merger 14
Inclinix Merges With PMG Research 14
Licensing Agreements 15
Aptiv Solutions Enters Into Licensing Agreement With Tessella For FACTS, Adaptive Trial Design Software 15
Debt Offering 16
ICON Raises USD350 Million in Private Placement of 3.64% Notes Due 2020 16
Acquisition 17
ICON Acquires Mapi 17
Icon Acquires Clinical Research Management 18
Icon Acquires PMG Research from Frontier Capital 19
ICON Acquires MediMedia Pharma Solutions for USD120 Million 20
Icon Completes Acquisition Of Aptiv Solutions For US$143.5 Million 21
Icon Completes Acquisition Of BeijingWits Medical Consulting, Contract Research Organization 23
ICON Plc – Key Competitors 24
ICON Plc – Key Employees 25
ICON Plc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 29
Strategy And Business Planning 29
Mar 29, 2018: ICON Helps Establish New Industry Standards Group to Improve Clinical Trial Collaboration and Execution 29
Mar 14, 2018: ICON opens a new office in Boston 30
Financial Announcements 31
Oct 24, 2018: ICON Reports Third Quarter 2018 Results 31
Oct 24, 2018: ICON reports third quarter 2018 results 33
Jul 25, 2018: ICON Reports Second Quarter 2018 Results 35
May 02, 2018: ICON Reports First Quarter 2018 Results 37
Feb 15, 2018: ICON Reports Fourth Quarter and Full Year 2017 Results 38
Jan 09, 2018: ICON Issues Financial Guidance for Full Year 2018 40
Oct 26, 2017: ICON Reports Third Quarter 2017 Results 41
Jul 27, 2017: ICON Reports Second Quarter 2017 Results 42
Apr 27, 2017: ICON Reports First Quarter 2017 Results 43
Feb 16, 2017: ICON Reports Fourth Quarter and Full Year 2016 Results 44
Jan 09, 2017: ICON Issues Financial Guidance for Full Year 2017 45
Corporate Communications 46
Jul 27, 2018: ICON Confirms Retirement of Co-Founder Dr. Ronan Lambe 46
Jan 09, 2018: ICON Appoints Dr. James Cummings as President of ClinicalRM 47
Nov 17, 2017: ICON Announces Appointment of Ms. Joan Garahy to Board of Directors 48
Oct 04, 2017: ICON Announces Appointment of Mr. Eugene McCague to Board of Directors 49
Government and Public Interest 50
Mar 27, 2018: Leading CROs Form New Industry Standards Group to Improve Collaboration with Sponsors 50
Product News 52
Nov 21, 2017: ICON Launches FIRECREST Pre-Screen to Improve the Speed and Accuracy of Identifying Eligible Patients for Screening 52
Nov 07, 2017: ICON contributes to major European research study that aims to improve treatment for traumatic brain injury 53
Feb 20, 2017: ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials 54
Other Significant Developments 55
Oct 01, 2018: ICON announces release of ADDPLAN Neo 55
Jun 22, 2018: ICON and DIA driving Insights to Action with DIA Live 2018 56
Apr 03, 2018: ICON announces launch of Government and Public Health Solutions to support global public health 57
Nov 21, 2017: FIRECREST Pre-Screen improves sponsor visibility of patient access 58
Nov 06, 2017: ICON Reveals Voice-Assistant Applications for Clinical Trials at ISPOR Annual European Congress 59
Oct 27, 2017: ICON and ICHOM unveil the world’s first global patient outcomes benchmarking platform 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
ICON Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ICON Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ICON Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ICON Plc, Deals By Therapy Area, 2012 to YTD 2018 9
ICON Plc, Medical Devices Deals, 2012 to YTD 2018 10
ICON Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Icon Completes Acquisition Of Clinical Trial Services Business From Cross Country Healthcare For Up To US$56 Million 12
Aptiv Solutions Raises US$5.7 Million In Venture Financing 13
Inclinix Merges With PMG Research 14
Aptiv Solutions Enters Into Licensing Agreement With Tessella For FACTS, Adaptive Trial Design Software 15
ICON Raises USD350 Million in Private Placement of 3.64% Notes Due 2020 16
ICON Acquires Mapi 17
Icon Acquires Clinical Research Management 18
Icon Acquires PMG Research from Frontier Capital 19
ICON Acquires MediMedia Pharma Solutions for USD120 Million 20
Icon Completes Acquisition Of Aptiv Solutions For US$143.5 Million 21
Icon Completes Acquisition Of BeijingWits Medical Consulting, Contract Research Organization 23
ICON Plc, Key Competitors 24
ICON Plc, Key Employees 25
ICON Plc, Subsidiaries 26

List of Figures
ICON Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ICON Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ICON Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ICON Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ICON Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ICON Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ICON Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ICON Plc (ICLR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sandoz Inc:企業のM&A・事業提携・投資動向
    Sandoz Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sandoz Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • AAS Balta:企業の戦略・SWOT・財務情報
    AAS Balta - Strategy, SWOT and Corporate Finance Report Summary AAS Balta - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • CMA CGM SA:企業のM&A・事業提携・投資動向
    CMA CGM SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CMA CGM SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Precision Optics Corporation Inc (PEYE):企業の財務・戦略的SWOT分析
    Summary Precision Optics Corporation Inc (Precision Optics) is a medical device company that designs, develops, manufactures and distributes optics and optical systems for medical, biomedical, and industrial applications. The company provides custom optics solutions such as design and prototyping, f …
  • Trina Solar Ltd-エネルギー分野:企業M&A・提携分析
    Summary Trina Solar Ltd (Trina Solar) is a vertically-integrated solar power products manufacturer. The company manufactures a wide variety of PV modules, both monocrystalline and multicrystalline; ingots, wafers, cells and solar modules. The company also designs, constructs, sells and operates sola …
  • Kiewit Corp:企業の戦略的SWOT分析
    Kiewit Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析
    Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that offers therapies. The company discovers and develops treatments for rare inherited diseases including liver and for cancers that are genetically defined. It offers RNAi technology platform GalXCTM, which is a advances …
  • miacom diagnostics GmbH:製品パイプライン分析
    Summary miacom diagnostics GmbH (miacom) is a molecular diagnostic company that develops and distributes molecular diagnostic tests. The company offers products such as hemoFISH, which identifies sepsis-related pathogens directly from positive blood culture bottles; respiFISH that identifies pathoge …
  • Novita Healthcare Ltd (NHL):医療機器:M&Aディール及び事業提携情報
    Summary Novita Healthcare Ltd (Novita Healthcare), formerly Avexa Ltd is a medical technology company that focuses on the measurement and treatment of attention difficulties in early childhood. The company operates through its subsidiary The Tali technology, which is developing a tablet based softwa …
  • Australian Broadcasting Corporation:企業の戦略的SWOT分析
    Australian Broadcasting Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • BGFIBank Group:企業の戦略・SWOT・財務分析
    BGFIBank Group - Strategy, SWOT and Corporate Finance Report Summary BGFIBank Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Matthews International Corp (MATW):企業の財務・戦略的SWOT分析
    Matthews International Corp (MATW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Seven Generations Energy Ltd (VII):企業の財務・戦略的SWOT分析
    Seven Generations Energy Ltd (VII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Serinus Energy plc (SEN):企業の財務・戦略的SWOT分析
    Summary Serinus Energy plc (Serinus), formerly Serinus Energy Inc, is an oil and gas company. It carries out exploration, development, and production of crude oil and natural gas assets in Romania and Tunisia. The company holds interest and operates Satu Mare Concession, an oil and gas exploration b …
  • Cassa Depositi e Prestiti SpA:石油・ガス:M&Aディール及び事業提携情報
    Summary Cassa Depositi e Prestiti SpA (CDP) is a financial service provider that offers banking and financial services. The company offers loans to state and regional governments, public bodies, local authorities, and public-law entities through postal savings products under state guarantee and the …
  • Industrial Bank Co., Ltd.:企業の戦略・SWOT・財務情報
    Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Applebee’s Restaurants LLC:企業の戦略・SWOT・財務情報
    Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report Summary Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Caladrius Biosciences Inc (CLBS):医療機器:M&Aディール及び事業提携情報
    Summary Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a clinical-stage biopharmaceutical company that develops cell therapy products. The company offers multiple technology platforms targeting cardiovascular indications and autoimmune diseases. The company’s lead product CLBS03 is …
  • Unimedic AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Unimedic AB (Unimedic), formerly Ergobe Pharma AB, a subsidiary of MedCap AB, is a pharmaceutical company which develops, manufactures, distributes and markets pharmaceutical products. The company offers non-licensed, extemporaneous, and licensed pharmaceuticals targeting the therapy areas w …
  • Shin-Etsu Chemical Co Ltd (4063):企業の財務・戦略的SWOT分析
    Shin-Etsu Chemical Co Ltd (4063) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆